Thomas Wallace currently serves as the Executive Medical Science Liaison for Rystiggo and Zilbrysq for Myasthenia Gravis at UCB, a position held since February 2023. Prior experience includes a notable tenure at Genentech from July 2009 to August 2025, where roles encompassed Senior Medical Science Liaison for Myasthenia Gravis, Alzheimer’s Disease, and Multiple Sclerosis, contributing to significant work with Ocrelizumab. Thomas also held various senior liaison roles at Roche and served as U.S. Medical Director for Rocephin. Academic credentials include a BA in Microbiology from Rutgers University, along with a Ph.D. in Pharmacology from Drexel University College of Medicine and additional studies at Washington University School of Medicine. A key publication co-authored in 2016 reflects expertise in the long-term safety and efficacy of Tocilizumab for adult rheumatoid arthritis.
This person is not in the org chart
This person is not in any teams
This person is not in any offices